Sanofi’s Zimulti NDA Resubmission Could Be Late 2008, At Earliest
Executive Summary
Sanofi-Aventis will likely not be able to resubmit the NDA for its obesity drug Zimulti (rimonabant) until the end of 2008, at the earliest, when data becomes available from its ongoing study of the drug in diabetes patients
You may also be interested in...
Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline
With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile
Clouds Over CB Antagonists Cast Light On Rest Of Obesity Pipeline
With big pharma's bet on cannabinoid-1 receptor antagonists for obesity shadowed by the safety concerns behind the withdrawal of Sanofi-Aventis' Zimulti (rimonabant) NDA, the weight of late-stage development could fall on centrally acting drugs that act on extensively-studied neurotransmitters, primarily serotonin, and peripherally acting agents that promise an improved side effect profile
Pharma Sales Growth: 2007 Starts High, But Expected To Taper By Year-End
BOSTON - Despite a strong start to 2007, growth in the pharmaceutical sector is expected to slow for the remainder of the year. According to IMS Health VP-Industry Relations Doug Long, "2007 has been a year that you could characterize as a fast start, slow finish.